Impact News +++ Micron Isn't Nvidia. It's Time to Take Your Foot Off the Gas with MU Stock. (Barchart) +++ MICRON Aktie +3,06%

EQUILLIUM Aktie

>EQUILLIUM Aktienkurs

2.28 EUR -6.9% (TradegateBSX)

Ask: 2.58 EUR / 2000 Stück

Bid: 2.38 EUR / 2200 Stück

Tagesumsatz: 500 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

EQUILLIUM Aktie über LYNX handeln

Intraday

1 Jahr

>EQUILLIUM Performance

1 Woche: +16,9%

1 Monat: +27,2%

3 Monate: +56,0%

6 Monate: +186,8%

1 Jahr: +580,6%

laufendes Jahr: +77,3%

>EQUILLIUM Aktie

Name:

EQUILLIUM INC. DL-,0001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US29446K1060 / A2N7B3

Symbol/ Ticker:

0FY (Frankfurt) / EQ (NASDAQ)

Kürzel:

FRA:0FY, ETR:0FY, 0FY:GR, NASDAQ:EQ

Index:

Webseite:

https://equilliumbio.com/

Profil:

Equillium, Inc. is a clinical-stage biotechnology company headquartered in La Jolla, California, focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with significant unmet medical needs. The company's lead p..
>Volltext..

Marktkapitalisierung:

157.27 Mio. EUR

Unternehmenswert:

104.83 Mio. EUR

Umsatz:

EBITDA:

-17.38 Mio. EUR

Nettogewinn:

-16.34 Mio. EUR

Gewinn je Aktie:

-0.28 EUR

Schulden:

0.59 Mio. EUR

Liquide Mittel:

52.6 Mio. EUR

Operativer Cashflow:

Bargeldquote:

18.33

Umsatzwachstum:

-100%

Gewinnwachstum:

-27.56%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

2 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 458.960 USD.

Suchwörter:

EQUILLIUM

Letzte Datenerhebung:

30.05.26

>EQUILLIUM Kennzahlen

Aktien/ Unternehmen:

Aktien: 63.23 Mio. St.

Frei handelbar: 76.32%

Leerverk. Aktien: 4.54%

Rückkaufquote: -35.82%

Mitarbeiter: 14

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Strong buy

Kursziel: 143.17%

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: 3.09

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -47.75%

Eigenkaprendite: -54.39%

>EQUILLIUM Peer Group

Gesundheit, Antikörper- Behandlung, Lungenerkrankungen & -behandlung/ Asthma, Hauterkrankungen & -behandlung/ Dermatologie, Autoimmunerkrankungen
>Alle Branchen..

>EQUILLIUM Chart & Kurs - NASDAQ

>EQUILLIUM News

30.05.26 - 03:01	Insiderhandel: Principal Accounting Officer verkauft Aktien von Equillium im Wert von 191750 USD (Insiderkauf)
	Tom, Penny - Vorstand - Tag der Transaktion: 2026-05-28...

30.05.26 - 03:01	Insiderhandel: Sr. Vice President and COO verkauft Aktien von Equillium im Wert von 26517 USD (Insiderkauf)
	Zedelmayer, Christine - Vorstand - Tag der Transaktion: 2026-05-27...

30.05.26 - 03:01	Insiderhandel: Sr. Vice President and COO verkauft Aktien von Equillium im Wert von 240693 USD (Insiderkauf)
	Zedelmayer, Christine - Vorstand - Tag der Transaktion: 2026-05-28...

28.05.26 - 22:09	Equillium to Participate in the 2026 Jefferies Global Healthcare Conference (GlobeNewswire EN)
	LA JOLLA, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 4:55pm EDT....

20.05.26 - 22:09	Equillium to Host Virtual Investor Event to Share New Insights into the Aryl Hydrocarbon Receptor (AhR) and miR-124 Axis (GlobeNewswire EN)
	Virtual webinar to be held on Wednesday, May 27 at 11:00 AM ET Virtual webinar to be held on Wednesday, May 27 at 11:00 AM ET...

13.05.26 - 22:42	Equillium GAAP EPS of -$0.06 misses by $0.02 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

13.05.26 - 22:03	Equillium Reports First Quarter 2026 Financial Results and Corporate Highlights (GlobeNewswire EN)
	Phase 1 proof-of-mechanism study of EQ504 on track to initiate in mid-2026, with data expected approximately six months thereafter...

01.05.26 - 22:45

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)

LA JOLLA, Calif., May 01, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on May 1, 2026, the Compensation Committee of Equillium's Board of Directors granted inducement awards consisting of nonstatutory stock options to purchase an aggregate of 800,000 shares of common stock to two new employees under Equillium's 2024 Inducement Plan. The Compensation Committee approved the stock option grants as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4)....

20.04.26 - 22:09	Equillium to Participate in Oppenheimer′s 2026 Innovation on the Island Event (GlobeNewswire EN)
	LA JOLLA, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will be presenting at Oppenheimer's 2026 Innovation on the Island Event on Tuesday April 28, 2026 at 7:50am AST....

08.04.26 - 14:33

Equillium Announces Poster Presentations at IMMUNOLOGY2026™, the Annual Meeting of the American Association of Immunologists (GlobeNewswire EN)

LA JOLLA, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that new EQ504 preclinical data have been accepted for poster presentations at IMMUNOLOGY2026™, the annual meeting of the American Association of Immunologists taking place in Boston, Massachusetts, April 15-19, 2026....

02.04.26 - 22:09

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)

LA JOLLA, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on April 1, 2026, the Compensation Committee of Equillium's Board of Directors granted an inducement award consisting of nonstatutory stock options to purchase a total of 32,000 shares of common stock to a new employee under Equillium's 2024 Inducement Plan. The Compensation Committee approved the stock option as an inducement material to such employee's employment in accordance with Nasdaq Listing Rule 5635(c)(4)....

25.03.26 - 22:03	Equillium GAAP EPS of -$0.04 beats by $0.02, revenue of $0M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

25.03.26 - 21:09	Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights (GlobeNewswire EN)
	Initiation of Phase 1 proof-of-mechanism study of EQ504 planned for mid-2026, with data expected approximately six months thereafter...

18.03.26 - 13:33	Equillium to Participate in the 38th Annual Roth Conference (GlobeNewswire EN)
	LA JOLLA, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the 38th Annual Roth Conference for Growth Companies on Monday, March 23, 2026 at 8:30am PT....

17.03.26 - 05:01	Insiderhandel: Sr. Vice President and COO verkauft Aktien von Equillium im Wert von 300816 USD (Insiderkauf)
	Zedelmayer, Christine - Vorstand - Tag der Transaktion: 2026-03-13...

13.03.26 - 13:24	Equillium stock jumps on $35M financing from RA Capital Management (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

13.03.26 - 13:03	Equillium Announces $35 Million Financing with RA Capital Management (GlobeNewswire EN)
	Capital strengthens the advancement of EQ504 through key clinical milestones...

12.03.26 - 19:01	Insiderhandel: Sr. Vice President and COO verkauft Aktien von Equillium im Wert von 362438 USD (Insiderkauf)
	Zedelmayer, Christine - Vorstand - Tag der Transaktion: 2026-03-09...

25.02.26 - 14:33	Equillium to Participate in the Leerink Partners 2026 Global Healthcare Conference (GlobeNewswire EN)
	LA JOLLA, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the Leerink Partners 2026 Global Healthcare Conference on Wednesday, March 11, 2026 at 10:40am ET....

23.02.26 - 20:01	Insiderhandel: Sr. Vice President and COO verkauft Aktien von Equillium im Wert von 328105 USD (Insiderkauf)
	Zedelmayer, Christine - Vorstand - Tag der Transaktion: 2026-02-19...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Also denk bei allem, was dich in Kummer versetzt, daran, folgenden Leitsatz anzuwenden: Nicht nur ist das kein Unglück, sondern es tapfer zu tragen ist ein Glück. - Mark Aurel

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram